US Pharma MarketingThe post Rivermark pockets $20m in Series D for late-stage prostate device trial appeared first on Medical Device Network.
Rivermark pockets $20m in Series D for late-stage prostate device trial
The raise will support Rivermark’s pivotal trial on its FloStent device, which is in development to treat patients with an enlarged prostate. The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for commercialisation. Rivermark will use the funds to continue a pivotal study on its prostatic stent, FloStent, while preparing the BPH device’s commercial readiness. Credit: M Isolation photo / Shutterstock.com. Wisconsin-based medtech Rivermark Medical has secured $20m in a Series D financing round – supporting the company’s late-stage clinical activities being used for approval of its flagship device for patients with…
The raise will support Rivermark’s pivotal trial on its FloStent device, which is in development to treat patients with an enlarged prostate.
Source: Medical Device Network